fbpx
QQQ
+ 6.24
313.10
+ 1.95%
DIA
+ 3.28
336.95
+ 0.96%
SPY
+ 5.77
404.40
+ 1.41%
TLT
+ 0.47
135.34
+ 0.35%
GLD
+ 1.02
170.13
+ 0.6%

Why Is It Moving? Analyzing The Upward Movement in Brooklyn ImmunoTherapeutics's Stock Today

April 6, 2021 10:02 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Brooklyn ImmunoTherapeutics's Stock Price And Volume Action

Brooklyn ImmunoTherapeutics, Inc. Common Stock (AMEX:BTX) is currently up 56.1% to a price of $7.84. The stock's volume is currently 17.06 million, which is roughly 1567.15% of its recent 30-day volume average of 1.09 million.

Why It's Moving

Benzinga Pro's real-time breaking news service shows some insight into what is affecting shares: Brooklyn ImmunoTherapeutics shares are trading higher after multiple Form 3 filings late Monday night showed new stakes by insiders. When an insider buys shares, the market may perceive it as a sign of confidence in the company's outlook.

Perspective On Recent Price Action

The moving average price of the stock over the past 50 days was $4.13 at the time this article was published. In the past fifty-two weeks, the stock price has been as high as $5.4 and as low as $3.59.

Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.

Posted-In:

Movers Trading Ideas

Related Articles

70 Biggest Movers From Yesterday

Gainers Nemaura Medical Inc. (NASDAQ: NMRD) shares surged 135.3% to close at $11.06 on Wednesday after the company receipt of a purchase order for 5,000 sugarBEAT transmitters and 200,000 sugarBEAT sensors from its U.K. licensee, DB Ethitronix Ltd. read more

50 Stocks Moving In Wednesday's Mid-Day Session

Gainers Nemaura Medical Inc. (NASDAQ: NMRD) shares jumped 64.9% to $7.75 after the company reported an order for 200,000 sugarBEAT sensors. read more

28 Stocks Moving in Wednesday's Pre-Market Session

Gainers Athenex, Inc. (NASDAQ: ATNX) shares rose 46.6% to $5.44 in pre-market trading after the company announced it acquired Kuur Therapeutics. read more

64 Biggest Movers From Yesterday

Gainers read more